IL37 and psoriasis: Compared with TNF-α inhibitors, the evidence of the HBVr risk in psoriasis patients receiving cytokine inhibitors (IL-12/23 inhibitor, IL-17 inhibitors, IL-23 inhibitor) was weak [8].